Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.54 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21381617 | 0.87 | PDE4B (0.43) | USP30KMT2ARORCPDE4BNAMPT | |
| SCHEMBL8053119 | 0.85 | PDE4B (0.48) | HDAC6HDAC1USP30KMT2ARORC | |
| SCHEMBL15376005 | 0.85 | RORC (0.49) | USP30KMT2ARORCPDE4BNAMPT | |
| SCHEMBL570083 | 0.83 | GPR119 (0.56) | USP30KMT2ARORCPDE4BNAMPT | |
| SCHEMBL21381667 | 0.83 | RORC (0.53) | RORCPDE4BNAMPTKDM4E | |
| SCHEMBL15187965 | 0.83 | RORC (0.56) | USP30RORCPDE4BNAMPTKDM4E | |
| SCHEMBL23119769 | 0.82 | RORC (0.44) | USP30KMT2ARORCPDE4BNAMPT | |
| SCHEMBL20607546 | 0.81 | RORC (0.48) | RORCPDE4BNAMPTKDM4E | |
| SCHEMBL17736163 | 0.81 | GPR119 (0.53) | KMT2ARORCPDE4BNAMPTKDM4E | |
| SCHEMBL23091747 | 0.81 | NAMPT (0.51) | RORCPDE4BNAMPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3713936-B1 | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2021-10-20 | — | — | EP | disclosed |
| US-11147275-B2 | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi | BASF SE (DE) | 2021-10-19 | — | — | US | disclosed |
| US-20200315177-A1 | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2020-10-08 | — | — | US | disclosed |
| EP-3713936-A1 | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2020-09-30 | — | — | EP | disclosed |
| WO-2019101511-A1 | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11147275-B2 | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi | CYP51A1, ERG28, PAOX | HDAC6 631/4885HDAC8 3012/4885HDAC1 1923/4885 |
| US-20200315177-A1 | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | CYP51A1, ERG28, PAOX | HDAC6 631/4885HDAC8 3012/4885HDAC1 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.